Therdsak Prammananan

Therdsak Prammananan

Auto-generated profile, based on publicly available information

Therdsak Prammananan

Drug-Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok 10700, Thailand

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2014 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
ASAngkanang Sowajassatakul
Angkanang Sowajassatakul
TPTherdsak Prammananan
Therdsak Prammananan
ACAngkana Chaiprasert
Angkana Chaiprasert
SPSaranya Phunpruch
Saranya Phunpruch
The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) makes the treatment and control of tuberculosis difficult. Rapid detection of drug-resistant strains is important for the successful treatment of drug-resistant tuberculosis; however, not all resistance mechanisms to the injectable second-line drugs such as amikacin (AK), kanamycin (KM), and capreomycin (CAP) are well understood. This study aims to validate the mechanisms associated with AK, KM, and CAP resistance in M. tuberculosis clinical strains isolated in Thailand.

20 August 2010 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
JJJirarut Jonmalung
Jirarut Jonmalung
TPTherdsak Prammananan
Therdsak Prammananan
MLManoon Leechawengwongs
Manoon Leechawengwongs
ACAngkana Chaiprasert
Angkana Chaiprasert
Background: Susceptibility testing of pyrazinamide (PZA) against Mycobacterium tuberculosis is difficult to perform because the acidity of culture medium that is required for drug activity also inhibits the growth of bacteria. In Thailand, very limited information has been generated on PZA resistance, particularly among multidrug-resistant tuberculosis (MDR-TB) isolated from Thailand. Only two studies on PZA susceptibility among Thai M. tuberculosis strains have been reported; one used a pyrazinamidase assay, and the other used the BACTEC 460 TB for PZA susceptibility testing. In this study, we determined the percentage of strains possessing pyrazinamide resistance among pan-susceptible M. tuberculosis and MDR-TB isolates by using the pyrazinamidase assay, BACTEC MGIT 960 PZA method and pncA sequencing, and assessed the correlation in the data generated using these methods. The type and frequency of mutations in pncA were also determined. Results: Overall, 150 M. tuberculosis isolates, consisting of 50 susceptible and 100 MDR-TB isolates, were tested for PZA susceptibility by BACTEC MGIT 960 PZA, the pyrazinamidase assay and pncA sequencing. The study indicated PZA resistance in 6% and 49% of susceptible and MDR-TB isolates, respectively. In comparison to the BACTEC MGIT 960 PZA, the PZase assay showed 65.4% sensitivity and 100% specificity, whereas pncA sequencing showed 75% sensitivity and 89.8% specificity. Twenty-four mutation types were found in this study, with the most frequent mutation (16%) being His71Asp. Of these mutations, eight have not been previously described. The Ile31Ser and Ile31Thr mutations were found both in PZA susceptible and resistant isolates, suggesting that mutation of this codon might not play a role on PZA resistance. Conclusions: Our findings suggest that phenotypic susceptibility testing is still essential for the detection of PZA resistance, especially for MDR-TB isolates. Some mutations were not associated with resistance and could lead to misinterpretation of the genotypic methods. This information could be helpful for clinicians in managing tuberculosis patients and frequencies, and the types of pncA mutations should offer baseline information on PZA resistance.

16 July 2018 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
ASAngkanang Sowajassatakul
Angkanang Sowajassatakul
TPTherdsak Prammananan
Therdsak Prammananan
ACAngkana Chaiprasert
Angkana Chaiprasert
SPSaranya Phunpruch
Saranya Phunpruch
Aminoglycosides such as amikacin and kanamycin are effective injectable second-line drugs for treatment of multidrug-resistant tuberculosis. Molecular mechanisms underlying aminoglycoside resistance are not well understood. We have previously identified the amikacin- and kanamycin-resistant M. tuberculosis MT433 clinical strain, of which all known mutations related to resistance have not been found. Drug efflux pump is one of reported resistance mechanisms that might play a role in aminoglycoside resistance. The expression levels of sixteen putative efflux pump genes, including eis and one regulator gene, whiB7, of MT433 in the presence of kanamycin were determined using the reverse transcription-quantitative PCR method. The effects of upregulated genes on amikacin and kanamycin resistance were investigated by overexpression in M. tuberculosis H37Ra strain. Upon kanamycin exposure, other than whiB7 and eis that were found extremely overexpressed, two drug efflux pump genes, namely Rv1877 and Rv2846c, showed specifically high-level of expression in M. tuberculosis MT433 strain. However, direct effect of overexpressed Rv1877 and Rv2846c on amikacin and kanamycin resistance could not be demonstrated in M. tuberculosis H37Ra overexpressed strain. Our finding demonstrated that overexpression of eis could occur without any mutations in the promoter region and be detectable in clinical isolate. This might be a consequence of overexpressed whiB7, resulting in amikacin and kanamycin resistance in M. tuberculosis MT433 strain.

12 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WJWansadaj Jaroenram
Wansadaj Jaroenram
JKJantana Kampeera
Jantana Kampeera
NANarong Arunrut
Narong Arunrut
SSSarawut Sirithammajak
Sarawut Sirithammajak
SJSarinya Jaitrong
Sarinya Jaitrong
WKWansika Kiatpathomchai
Wansika Kiatpathomchai
Mycobacterium tuberculosis (Mtb) is an insidious scourge that has afflicted millions of people worldwide. Although there are many rapid methods to detect it based on loop-mediated isothermal amplification (LAMP) and a lateral flow dipstick (LFD), this study made further improvements using a new set of primers to enhance LAMP performance and a novel DNA probe system to simplify detection and increase specificity. The new probe system eliminates the post-LAMP hybridization step typically required for LFD assays by allowing co-hybridization and amplification of target DNA in one reaction while preventing self-polymerization that could lead to false-positive results. The improved assay was named Probe-Triggered, One-Step, Simultaneous DNA Hybridization and LAMP Integrated with LFD (SH-LAMP-LFD). SH-LAMP-LFD was simpler to perform and more sensitive than previously reported LAMP-LFD and PCR methods by 100 and 1000 times, respectively. It could detect a single cell of Mtb. The absence of cross-reactivity with 23 non-TB bacteria, and accurate test results with all 104 blind clinical samples have highlighted its accuracy. Its robustness and portability make SH-LAMP-LFD suitable for users in both low and high resource settings.

1 July 2009 in Tuberculosis
Verified
Journal Article
Closed access
JYJutaporn Yorsangsukkamol
Jutaporn Yorsangsukkamol
ACAngkana Chaiprasert
Angkana Chaiprasert
TPTherdsak Prammananan
Therdsak Prammananan
PPPrasit Palittapongarnpim
Prasit Palittapongarnpim
SLSunsern Limsoontarakul
Sunsern Limsoontarakul
NPNaraporn Prayoonwiwat
Naraporn Prayoonwiwat

1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
PSPrapaporn Srilohasin
Prapaporn Srilohasin
TPTherdsak Prammananan
Therdsak Prammananan
KFKiatichai Faksri
Kiatichai Faksri
JPJody E. Phelan
Jody E. Phelan
PSPrapat Suriyaphol
Prapat Suriyaphol
ACAngkana Chaiprasert
Angkana Chaiprasert
Tuberculosis disease (TB), caused by Mycobacterium tuberculosis, is a major public health issue in Thailand. The high prevalence of modern Beijing (Lineage 2.2.1) strains has been associated with multi- and extensively-drug resistant infections (MDR-, XDR-TB), complicating disease control. The impact of rarer proto-Beijing (L2.1) strains is less clear. In our study of thirty-seven L2.1 clinical isolates spanning thirteen years, we found a high prevalence of XDR-TB cases (32.4%). With ≤ 12 pairwise SNP distances, 43.2% of L2.1 patients belong to MDR-TB or XDR-TB transmission clusters suggesting a high level of clonal expansion across four Thai provinces. All XDR-TB (100%) were likely due to transmission rather than inadequate treatment. We found a 47 mutation signature and a partial deletion of the fadD14 gene in the circulating XDR-TB cluster, which can be used for surveillance of this rare and resilient M. tuberculosis strain-type that is causing increasing health burden. We also detected three novel deletion positions, a deletion of 1,285 bp within desA3 (Rv3230c), large deletions in the plcB, plcA, and ppe38 gene which may play a role in the virulence, pathogenesis or evolution of the L2.1 strain-type.